HSE - PCRS

Application Details

HSE Application ID

HSE100042

HTA Number

25031

HTA Link

https://www.ncpe.ie/avapritinib-ayvakyt-hta-id-25031/

Drug

avapritinib

Brand

Ayvakyt®

Applicant

Blueprint Medicines

Indication Applied For

Indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy.

Application Date

14/04/2025

Marketing Authorisation Date

24/03/2022

Application Status

HSE Drugs Group Review Pending

18/12/2025

Proposal from Applicant Under Review

16/12/2025

Awaiting Proposal from Applicant

23/10/2025

Applicant Meeting Held with CPU

23/10/2025

Full Health Technology Assessment Commissioned by HSE

30/05/2025

Rapid Review Completed

15/05/2025

Rapid Review Commissioned

14/04/2025

Pricing and Reimbursement Application Complete

14/04/2025

New Search